- Home
- QSI vs MLYS Comparison
QSI vs MLYS Comparison
Compare QSI & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QSI
- MLYS
- Stock Information
- Founded
- QSI 2013
- MLYS 2019
- Country
- QSI United States
- MLYS United States
- Employees
- QSI N/A
- MLYS N/A
- Industry
- QSI Biotechnology: Pharmaceutical Preparations
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- QSI Health Care
- MLYS Health Care
- Exchange
- QSI Nasdaq
- MLYS Nasdaq
- Market Cap
- QSI 219.8M
- MLYS 1.0B
- IPO Year
- QSI N/A
- MLYS 2023
- Fundamental
- Price
- QSI $1.96
- MLYS $13.84
- Analyst Decision
- QSI Strong Buy
- MLYS Strong Buy
- Analyst Count
- QSI 3
- MLYS 4
- Target Price
- QSI $2.38
- MLYS $27.00
- AVG Volume (30 Days)
- QSI 7.9M
- MLYS 827.2K
- Earning Date
- QSI 08-06-2025
- MLYS 08-12-2025
- Dividend Yield
- QSI N/A
- MLYS N/A
- EPS Growth
- QSI N/A
- MLYS N/A
- EPS
- QSI N/A
- MLYS N/A
- Revenue
- QSI $3,443,000.00
- MLYS N/A
- Revenue This Year
- QSI $77.57
- MLYS N/A
- Revenue Next Year
- QSI $251.34
- MLYS N/A
- P/E Ratio
- QSI N/A
- MLYS N/A
- Revenue Growth
- QSI 167.94
- MLYS N/A
- 52 Week Low
- QSI $0.61
- MLYS $8.24
- 52 Week High
- QSI $5.77
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- QSI 59.83
- MLYS 42.26
- Support Level
- QSI $1.87
- MLYS $12.95
- Resistance Level
- QSI $2.14
- MLYS $14.09
- Average True Range (ATR)
- QSI 0.14
- MLYS 0.77
- MACD
- QSI 0.02
- MLYS -0.14
- Stochastic Oscillator
- QSI 69.49
- MLYS 28.24
About QSI Quantum-Si Incorporated
Quantum-Si Inc is a life sciences company focused on the development and commercialization of proteomics research tools. The company has designed and developed a hardware, consumable, and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform that enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.